Aurobindo subsidiary gets license to develop and market Nilotinib Capsules in LMICs

Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market Nilotinib Capsules.

Originally developed by Novartis, Nilotinib Capsules are used for the treatment of chronic myeloid leukemia (CML) in 44 low and middle-income countries (LMIC). This agreement covers seven countries where patents for the product are pending or in force.

Under the agreement, Eugia Pharma Specialities will produce Nilotinib Capsules at its facility in Medchal, Malkajgiri District, Telangana, India. The company’s state-of-the-art manufacturing unit is equipped to meet the global demand for the product across the licensed territory, ensuring high-quality production standards.

K Nithyananda Reddy — Aurobindo Pharma Vice Chairman and Managing Director said: “This product will be a good addition to Aurobindo’s Oncology portfolio and will further strengthen our leadership in the generic Oncology medicine space. We are looking forward to supplying the product at the earliest and helping to reduce the risk of chronic myeloid leukemia (CML) in certain patients.”

Nilotinib is indicated for the treatment of various forms of chronic myeloid leukemia (CML). It is used in adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase, as well as adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia with resistance or intolerance to prior therapy, including imatinib.

Additionally, it is prescribed for pediatric patients with chronic phase Philadelphia chromosome positive chronic myeloid leukemia who have resistance or intolerance to prior therapy.

Aurobindo Pharma’s partnership with Medicines Patent Pool and the development of generic Nilotinib capsules reflect their commitment to expanding access to affordable oncology treatments in LMICs. This initiative will contribute to reducing the burden of cancer in these countries and improve patient outcomes.